Skip to main content
TipRanks
Go Ultimate75% OFF

China Health Group Inc. (8225) AI Stock Analysis

0 Followers
HK:8225

China Health Group Inc.

(HKEX:8225)

Select Model
Rating:42Neutral
Price Target:HKD 0.06â–¼(-34.83% Downside)
Action:reiterated
Date:11/05/26

The score is driven primarily by persistent unprofitability, eroding equity, and weak technical momentum. Zero debt and positive operating cash flow provide limited support, but the negative P/E and lack of dividend yield reinforce the high-risk profile.

Positive Factors
No reported debtThe absence of reported debt limits interest obligations and refinancing exposure, giving the company greater financial flexibility than a highly leveraged peer. This cushion can help preserve resources for operations and investment even while profitability remains weak.
Negative Factors
Persistent net lossesMulti-year losses indicate that the business has not yet demonstrated a sustainable earnings model. A TTM net margin near -52% means revenue is currently insufficient to cover the full cost base, limiting reinvestment capacity and increasing pressure on the capital base.

China Health Group Inc. (8225) vs. iShares MSCI Hong Kong ETF (EWH)

-80%-60%-40%-20%0%20%HK:8225-42.95%EWH+8.92%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 88.59M
Dividend Yield
―
Average Volume (3M)
305.83K
Price to Earnings (P/E)
-3.5
Beta (1Y)
0.15
Revenue Growth
5.27%
EPS Growth
-4.86%
Country
Hong Kong
Employees
33
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

China Health Group Inc. Business Overview & Revenue Model

Company Description

China Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People’s Republic of China. The company offers contracted pharmaceutical development and clinical research, an...

China Health Group Inc. Financial Statement Overview

Summary

Persistent losses, a shrinking equity base, and volatile cash flow weigh heavily on performance. Zero debt and positive 2024 operating cash flow provide some stability.

Income Statement

25Negative

Balance Sheet

65Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue31.92M27.82M26.45M21.43M13.09M83.60M
Gross Profit17.58M15.97M10.07M8.21M5.74M63.86M
EBITDA-2.66M-14.05M-14.24M-57.98M-15.66M42.74M
Net Income-14.57M-14.57M-14.52M-58.01M-15.84M36.33M
Balance Sheet
Total Assets87.11M87.11M100.96M119.35M178.63M194.32M
Cash, Cash Equivalents and Short-Term Investments25.16M25.16M15.89M7.30M12.07M17.02M
Total Debt000000
Total Liabilities32.33M32.33M31.24M35.17M36.74M42.54M
Stockholders Equity55.41M55.41M70.35M84.82M142.32M155.57M
Cash Flow
Free Cash Flow7.58M9.02M8.52M-4.88M-5.16M-10.28M
Operating Cash Flow7.59M9.03M10.28M1.12M-5.16M-10.28M
Investing Cash Flow35.00K-34.09K-230.00K-1.04M-2.15M6.96M
Financing Cash Flow00000-1.51M

China Health Group Inc. Technical Analysis

Technical Analysis SentimentPositive
Last Price0.09

Price Trends

50DMA0.07Positive
100DMA0.08Positive
200DMA0.11Negative

Market Momentum

MACD-0.00Negative
RSI77.37Negative
STOCH36.11Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8225, the sentiment is Positive. The current price of 0.09 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and below the 200-day MA of 0.11, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 77.37 is Negative, neither overbought nor oversold. The STOCH value of 36.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8225.

China Health Group Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:8225 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:2359HK:235975OutperformHKD 514.93B15.7330.77%1.26%38.26%84.56%
HK:6127HK:612772OutperformHKD 33.50B26.8713.10%0.62%16.68%442.43%
HK:3347HK:334755NeutralHKD 39.88B-97.83-2.00%0.41%21.72%-169.67%
HK:6667HK:666754NeutralHKD 1.50B47.744.04%2.54%169.02%-24.61%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:8225HK:822542NeutralHKD 88.59M-3.51-15.01%―5.27%-4.86%

* Healthcare Sector Average

Performance Comparison

0%100%200%HK:8225HK:3347HK:2359HK:6127HK:6667HK:8247Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:8225 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:8225China Health Group Inc.0.09-0.07-42.95%
HK:3347Hangzhou Tigermed Consulting Co., Ltd. Class H35.28-5.43-13.34%
HK:2359WuXi AppTec Co., Ltd. Class H189.5087.3585.51%
HK:6127JOINN Laboratories (China) Co., Ltd. Class H22.184.4625.18%
HK:6667Mega Genomics Limited6.68-0.35-4.94%
HK:8247Biosino Bio-Technology & Science, Inc. Class H2.600.8044.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026